Upgrading the therapeutic potential of catechin against Ehrlich carcinoma and mitigating oxidative stress in the liver employing chitosan polyaspartate as nanodelivery vehicles.

Mohammad Y Alfaifi, Mustafa R Abdulbaqi, Wesam Abd El-Fattah, Ali A Shati, Serag Eldin I Elbehairi, Reda F M Elshaarawy, Waleed M Serag, Yasser A Hassan

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohammad Y AlfaifiCentral Labs, King Khalid University Alqura'a, P. O. Box 960 Abha Saudia Arabia.

Mustafa R AbdulbaqiDepartment of pharmaceutics, College of Pharmacy, Al-Naji University Baghdad Iraq.

Wesam Abd El-FattahDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU) P. O. Box 5701 Riyadh 11432 Saudi Arabia.

Ali A ShatiCentral Labs, King Khalid University Alqura'a, P. O. Box 960 Abha Saudia Arabia.

Serag Eldin I ElbehairiCentral Labs, King Khalid University Alqura'a, P. O. Box 960 Abha Saudia Arabia.

Reda F M ElshaarawyDepartment of Chemistry, Faculty of Science, Suez University 43533 Suez Egypt waleed.ibrahim@suezuniv.edu.eg.ORCID https://orcid.org/0000-0003-2100-8928

Waleed M SeragDepartment of Chemistry, Faculty of Science, Suez University 43533 Suez Egypt waleed.ibrahim@suezuniv.edu.eg.ORCID https://orcid.org/0000-0002-0136-9307

Yasser A HassanDepartment of pharmaceutics, College of Pharmacy, Al-Kitab University Kirkuk 36015 Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to design and develop new chitosan polyaspartate nanovehicles (CPANVs) to enhance the targeting delivery and bioavailability of catechin (CAT). Thus, augmenting its anticancer efficacy against Ehrlich ascites carcinoma (EAC) in the peritoneal cavities of Swiss albino mice and without impairing the liver or its functions. Initially, CAT@CPANVs were synthesized through double emulsification followed by ionotropic gelation processes, and the physicochemical and morphological characteristics of this nanoformulation were investigated. Thereafter, the

Identifiers

PMID41356717

DOI10.1039/d5ra06086a

PMCPMC12679257

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.